Lighthouse Investment Partners LLC Has $3.31 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Lighthouse Investment Partners LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 148.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,500 shares of the company's stock after acquiring an additional 23,000 shares during the quarter. Lighthouse Investment Partners LLC's holdings in Novo Nordisk A/S were worth $3,312,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Center for Financial Planning Inc. increased its holdings in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL increased its holdings in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Transce3nd LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $33,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $39,000. Finally, Albion Financial Group UT increased its holdings in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after purchasing an additional 278 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 2.6%

Shares of NVO stock traded up $1.66 on Thursday, hitting $66.07. 9,052,066 shares of the stock were exchanged, compared to its average volume of 6,487,417. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $296.49 billion, a P/E ratio of 20.08, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The business has a 50-day moving average of $67.84 and a 200 day moving average of $85.23. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent analyst reports. Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Finally, Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.